The 20-week pilot tests three distinct products with one evidence standard: baseline first, governed action second, verified outcome last.
Medication changes, repeat authorisations, dispensing, administration and pathway activity can sit across different systems and organisations. Visibility does not guarantee that downstream work is complete.
Sitora creates accountable signals and events around those systems, routes action to the right professional and records whether the loop, supply decision or resource opportunity was actually resolved.
Close medication changes across organisations.
Population: Hospital discharge and other cross-setting changes affecting GP, pharmacy, care-home or community workflows.
Primary outcomes: Open-loop rate, time-to-reconcile, downstream acknowledgements, discrepancies resolved, obsolete supply prevented and safety.
Prevent repeat supply that may no longer be required.
Population: Selected repeat-medicine cohorts where cumulative supply, stock or change history can be assessed safely.
Primary outcomes: Reviews triggered, supplies deferred, dispensing outcome, intervention workload, safety and verified cost avoidance.
Identify and verify lower-resource clinically appropriate pathways.
Population: Selected high-volume or resource-intensive injectable, SACT or preparation pathways.
Primary outcomes: Pharmacy/nursing minutes, chair or bed capacity, unused doses, pathway cost, patient impact and safety.
Confirm sponsor, sites, governance, data flows, safety boundaries and baseline definitions.
Measure cross-setting medication discrepancies, repeat-supply signals, pathway resource use and workload.
Run controlled, human-reviewed workflows in shadow mode first, then approved live use.
Verify closure, avoided supply, resource recovery, safety and net operational effect.
Clinical discrepancy resolution, cash release, cost avoidance and capacity release are not interchangeable. Each product keeps its own denominator and outcome definition.
Exact regulatory applicability depends on intended use and deployment architecture.
Named clinical leadership, hazard logging, escalation rules, human review and no autonomous prescribing changes.
DPIA, data-flow mapping, minimisation, role-based access, provenance and audit logging.
Read-only integration first, visible source conflicts, no silent overwrite and explicit acknowledgement states.
Pre-agreed outcomes and finance validation before any cash-releasing claim is reported.
The technical plan defines source systems, minimum data, event ownership, acknowledgement states, audit requirements and deployment gates.
Open technical plan